Results 131 to 140 of about 280,167 (140)

“IT WOULD PUT IT IN THEIR OWN HANDS”: HEALTHCARE PROVIDERS’ PERSPECTIVES TOWARDS PATIENT SELF-ADMINISTRATION OF SUBCUTANEOUS MEDROXYPROGESTERONE ACETATE (DMPA-SC)

Contraception, 2023
F. Lawal, R. Hubach, K. LaRoche
semanticscholar   +1 more source

National Policy Landscape Analysis on DMPA-SC: Pakistan Final Report

2023
Azmat, Syed Khurram, Awan, Muhammad Ali
openaire   +1 more source

Subcutaneous depo-medroxyprogesterone acetate (DMPA-SC) use in obese and morbidly obese women: incidence of ovulation and follicular development

2015
Background: Subcutaneous depo-medroxyprogesterone acetate (DMPA-SC) has not been studied in the morbidly obese population. The purpose of this 26-week prospective experimental study is to determine incidence of ovulation and follicular development among obese and morbidly obese women after DMPA-SC.
openaire   +1 more source

DMPA-IM, DMPA-SC: Side Effect Differences Few

Pediatric News, 2010
openaire   +1 more source

Providing contraception to trans youth: a qualitative study investigating the acceptability of DMPA-SC and prior experiences with contraceptive counseling.

Journal of Pediatric and Adolescent Gynecology
Nicholas R.W. Cleland, Charlie E. Graves, Lauren M. Reade, Natalie J. Nokoff, Ryan P. O’Connell, Nancy Z. Fang   +5 more
semanticscholar   +1 more source

Investigational DMPA-SC Treats Endometriosis Pain, Curbs BMD Loss

Ob.Gyn. News, 2005
openaire   +1 more source

DMPA SC dataset

2019
openaire   +1 more source

Few Side Effect Differences Between DMPA-IM, DMPA-SC

Family Practice News, 2010
openaire   +1 more source

DMPA-SC 104 has significantly less impact on bone mineral density than leuprolide acetate in patients with endometriosis

Contraception, 2005
DF Archer, JC Gallagher
openaire   +1 more source

DMPA-SC 104 provides similar duration of posttreatment relief from the symptoms of endometriosis as compared with leuprolide acetate

Contraception, 2005
WD Schlaff, SA Carson
openaire   +1 more source